REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 257.47 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-07-29
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 45.98K shares, a 27.51% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 211.49K shares, a 12.21% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 13.13K shares, a 20.05% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 29.50K shares, a 31.92% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 294.54K shares, a 26.67% increase from fiscal 2024.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 232.52K shares, a 9.50% increase from fiscal 2023.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 212.34K shares, a 9.10% increase from fiscal 2022.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 194.63K shares, a 3.76% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 45.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | 257.47K shares 10-Q · filed 2026-07-29 | 270.60K shares derived: sum of 3 quarters · filed 2026-07-29 | 300.10K shares derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | 211.49K shares 10-Q · filed 2026-05-06 | 224.62K shares derived: sum of 2 quarters · filed 2026-05-06 | 254.12K shares derived: sum of 3 quarters · filed 2026-05-06 | 317.55K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 13.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 42.63K shares derived: sum of 2 quarters · filed 2026-02-26 | 106.06K shares derived: sum of 3 quarters · filed 2026-02-26 | 294.54K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 29.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 92.94K shares derived: sum of 2 quarters · filed 2025-11-04 | 281.41K shares 10-Q · filed 2025-11-04 | 292.35K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 63.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 251.91K shares 10-Q · filed 2025-08-07 | 262.84K shares derived: sum of 3 quarters · filed 2025-08-07 | 306.18K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 188.47K shares 10-Q · filed 2025-04-29 | 199.41K shares derived: sum of 2 quarters · filed 2025-04-29 | 242.74K shares derived: sum of 3 quarters · filed 2025-04-29 | 268.51K shares derived: sum of 4 quarters · filed 2025-04-29 |
| 2024-12-31 | 10.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | 54.27K shares derived: sum of 2 quarters · filed 2025-03-14 | 80.04K shares derived: sum of 3 quarters · filed 2025-03-14 | 232.52K shares 10-K · filed 2025-03-14 |
| 2024-09-30 | 43.33K shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-18 | 69.10K shares derived: sum of 2 quarters · filed 2024-11-18 | 221.58K shares 10-Q · filed 2024-11-18 | 258.45K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2024-06-30 | 25.77K shares derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | 178.25K shares 10-Q/A · filed 2024-11-18 | 215.12K shares derived: sum of 3 quarters · filed 2024-11-18 | 232.51K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2024-03-31 | 152.48K shares 10-Q/A · filed 2024-11-18 | 189.35K shares derived: sum of 2 quarters · filed 2024-11-18 | 206.74K shares derived: sum of 3 quarters · filed 2024-11-18 | 233.89K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-12-31 | 36.86K shares derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-11-18 | 54.25K shares derived: sum of 2 quarters · filed 2024-11-18 | 81.41K shares derived: sum of 3 quarters · filed 2024-11-18 | 212.34K shares 10-K/A · filed 2024-11-18 |
| 2023-09-30 | 17.39K shares derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | 44.55K shares derived: sum of 2 quarters · filed 2024-11-18 | 175.47K shares 10-Q/A · filed 2024-11-18 | 210.99K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | 27.16K shares derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | 158.08K shares 10-Q/A · filed 2024-11-18 | 193.60K shares derived: sum of 3 quarters · filed 2024-11-18 | 207.87K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | 130.93K shares 10-Q/A · filed 2024-11-18 | 166.44K shares derived: sum of 2 quarters · filed 2024-11-18 | 180.72K shares derived: sum of 3 quarters · filed 2024-11-18 | 201.42K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | 35.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | 49.79K shares derived: sum of 2 quarters · filed 2023-02-22 | 70.49K shares derived: sum of 3 quarters · filed 2023-02-22 | 194.63K shares 10-K · filed 2023-02-22 |
| 2022-09-30 | 14.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 34.98K shares derived: sum of 2 quarters · filed 2022-11-01 | 159.12K shares 10-Q · filed 2022-11-01 | |
| 2022-06-30 | 20.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | 144.84K shares 10-Q · filed 2022-08-02 | ||
| 2022-03-31 | 124.14K shares 10-Q · filed 2022-04-27 | |||
| 2021-12-31 | 187.59K shares 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |